| Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates YJ Yu, JK Atwal, Y Zhang, RK Tong, KR Wildsmith, C Tan, N Bien-Ly, ... Science translational medicine 6 (261), 261ra154-261ra154, 2014 | 374 | 2014 |
| Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants N Bien-Ly, YJ Yu, D Bumbaca, J Elstrott, CA Boswell, Y Zhang, W Luk, ... The Journal of experimental medicine 211 (2), 233, 2014 | 334 | 2014 |
| Discovery of novel blood-brain barrier targets to enhance brain uptake of therapeutic antibodies YJY Zuchero, X Chen, N Bien-Ly, D Bumbaca, RK Tong, X Gao, S Zhang, ... Neuron 89 (1), 70-82, 2016 | 260 | 2016 |
| A strategy for risk mitigation of antibodies with fast clearance I Hötzel, FP Theil, LJ Bernstein, S Prabhu, R Deng, L Quintana, J Lutman, ... MAbs 4 (6), 753-760, 2012 | 241* | 2012 |
| Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody–drug conjugates in rats CA Boswell, EE Mundo, C Zhang, D Bumbaca, NR Valle, KR Kozak, ... Bioconjugate chemistry 22 (10), 1994-2004, 2011 | 233 | 2011 |
| Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor R Deng, D Bumbaca, CV Pastuskovas, CA Boswell, D West, KJ Cowan, ... MAbs 8 (3), 593-603, 2016 | 188 | 2016 |
| Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1) H Uppal, E Doudement, K Mahapatra, WC Darbonne, D Bumbaca, ... Clinical Cancer Research 21 (1), 123-133, 2015 | 182 | 2015 |
| Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells G Li, J Guo, BQ Shen, DB Yadav, MX Sliwkowski, LM Crocker, JA Lacap, ... Molecular cancer therapeutics 17 (7), 1441-1453, 2018 | 150 | 2018 |
| Structure of a protein–DNA complex essential for DNA protection in spores of Bacillus species KS Lee, D Bumbaca, J Kosman, P Setlow, MJ Jedrzejas Proceedings of the National Academy of Sciences 105 (8), 2806-2811, 2008 | 147 | 2008 |
| Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism BQ Shen, D Bumbaca, O Saad, Q Yue, C V Pastuskovas, ... Current drug metabolism 13 (7), 901-910, 2012 | 139 | 2012 |
| Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration Y Zheng, DB Tesar, L Benincosa, H Birnböck, CA Boswell, D Bumbaca, ... MAbs 4 (2), 243-255, 2012 | 132 | 2012 |
| Antibody-mediated targeting of tau in vivo does not require effector function and microglial engagement SH Lee, CE Le Pichon, O Adolfsson, V Gafner, M Pihlgren, H Lin, ... Cell reports 16 (6), 1690-1700, 2016 | 127 | 2016 |
| Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics D Bumbaca, CA Boswell, PJ Fielder, LA Khawli The AAPS journal 14, 554-558, 2012 | 126 | 2012 |
| Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model CV Pastuskovas, EE Mundo, SP Williams, TK Nayak, J Ho, S Ulufatu, ... Molecular cancer therapeutics 11 (3), 752-762, 2012 | 123 | 2012 |
| Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4 D Bumbaca, A Wong, E Drake, AE Reyes II, BC Lin, JP Stephan, ... MAbs 3 (4), 376-386, 2011 | 116* | 2011 |
| A novel in vitro method to model the fate of subcutaneously administered biopharmaceuticals and associated formulation components HM Kinnunen, V Sharma, LR Contreras-Rojas, Y Yu, C Alleman, ... Journal of Controlled Release 214, 94-102, 2015 | 98 | 2015 |
| Quantitative cumulative biodistribution of antibodies in mice: effect of modulating binding affinity to the neonatal Fc receptor V Yip, E Palma, DB Tesar, EE Mundo, D Bumbaca, EK Torres, NA Reyes, ... MAbs 6 (3), 689-696, 2014 | 78 | 2014 |
| Evaluating the use of antibody variable region (Fv) charge as a risk assessment tool for predicting typical cynomolgus monkey pharmacokinetics DB Yadav, VK Sharma, CA Boswell, I Hotzel, D Tesar, Y Shang, Y Ying, ... Journal of Biological Chemistry 290 (50), 29732-29741, 2015 | 75 | 2015 |
| Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer’s disease G Ayalon, SH Lee, O Adolfsson, C Foo-Atkins, JK Atwal, M Blendstrup, ... Science Translational Medicine 13 (593), eabb2639, 2021 | 67 | 2021 |
| Comparative physiology of mice and rats: radiometric measurement of vascular parameters in rodent tissues CA Boswell, EE Mundo, S Ulufatu, D Bumbaca, HS Cahaya, N Majidy, ... Molecular pharmaceutics 11 (5), 1591-1598, 2014 | 67 | 2014 |
